Literature DB >> 26925709

Early Posttherapy Hospitalizations Among Survivors of Childhood Leukemia and Lymphoma.

Andrew B Smitherman1, Tania M Wilkins, Julie Blatt, Stacie B Dusetzina.   

Abstract

Long-term survivors of childhood cancers are at increased risk for hospitalization. To test the hypothesis that many treatment-related morbidities are identifiable in the early posttherapy period, we determined the rates and causes for hospitalization among survivors of leukemia and lymphoma during the first 3 years posttherapy. Using a health plan claims database, we identified patients aged 0 to 21 years old treated for leukemia or lymphoma from 2000 to 2010. Survivors were matched 10:1 with similar children without a history of cancer. Hospitalization rates over 3 years were compared using Cox proportional hazards regression and risks of cause-specific hospitalization were compared using log-binomial models. Nineteen percent of childhood leukemia and lymphoma survivors were hospitalized in the first 3 years off therapy. Leukemia survivors (N=529) experienced over 6 times (hazard ratio=6.3; 95% confidence interval [CI], 4.9-8.0) and lymphoma survivors (N=454) over 3 times the hospitalization rate of controls (hazard ratio=3.2; 95% CI, 2.5-4.2). Compared with children without a cancer history, survivors were at increased risk for hospitalization due to infectious causes (leukemia: relative risk [RR], 60.0; 95% CI, 23.4-154.0; lymphoma: RR, 10.0; 95% CI, 4.4-22.9). In addition, lymphoma survivors were at increased risk for cardiovascular-related (RR, 15.0; 95% CI, 5.4-42.0) and pulmonary-related (RR, 8.1; 95% CI, 3.9-16.8) hospitalizations. These findings highlight the morbidity experienced by survivors and suggest that treatment-associated complications may be emerging soon after therapy completion.

Entities:  

Mesh:

Year:  2016        PMID: 26925709      PMCID: PMC4955640          DOI: 10.1097/MPH.0000000000000548

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  18 in total

1.  Late cardiotoxicity after treatment for Hodgkin lymphoma.

Authors:  Berthe M P Aleman; Alexandra W van den Belt-Dusebout; Marie L De Bruin; Mars B van 't Veer; Margreet H A Baaijens; Jan Paul de Boer; Augustinus A M Hart; Willem J Klokman; Marianne A Kuenen; Gabey M Ouwens; Harry Bartelink; Flora E van Leeuwen
Journal:  Blood       Date:  2006-11-21       Impact factor: 22.113

2.  Long-term pulmonary sequelae after treatment of childhood Hodgkin's disease.

Authors:  G Bossi; I Cerveri; E Volpini; A Corsico; A Baio; F Corbella; C Klersy; M Arico
Journal:  Ann Oncol       Date:  1997       Impact factor: 32.976

3.  Hospitalisations 1998-2000 in a British Columbia population-based cohort of young cancer survivors: report of the Childhood/Adolescent/Young Adult Cancer Survivors (CAYACS) Research Program.

Authors:  Nicole M E Bradley; Maria F Lorenzi; Zenaida Abanto; Sam Sheps; Anne Marie Broemeling; John J Spinelli; Karen Goddard; Sheila Pritchard; Paul Rogers; Mary L McBride
Journal:  Eur J Cancer       Date:  2010-06-08       Impact factor: 9.162

4.  Risk of hospitalization for survivors of childhood and adolescent cancer.

Authors:  Anne C Kirchhoff; Mark N Fluchel; Jennifer Wright; Jian Ying; Carol Sweeney; Julia Bodson; Antoinette M Stroup; Ken R Smith; Alison Fraser; Anita Y Kinney
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-06-12       Impact factor: 4.254

5.  Hospital contact for mental disorders in survivors of childhood cancer and their siblings in Denmark: a population-based cohort study.

Authors:  Lasse Wegener Lund; Jeanette F Winther; Susanne O Dalton; Luise Cederkvist; Pia Jeppesen; Isabelle Deltour; Marie Hargreave; Susanne K Kjær; Allan Jensen; Catherine Rechnitzer; Klaus K Andersen; Kjeld Schmiegelow; Christoffer Johansen
Journal:  Lancet Oncol       Date:  2013-08-14       Impact factor: 41.316

6.  Hospitalization Rates Among Survivors of Young Adult Malignancies.

Authors:  Devon P Richardson; Corinne Daly; Rinku Sutradhar; Lawrence F Paszat; Andrew S Wilton; Linda Rabeneck; Nancy N Baxter
Journal:  J Clin Oncol       Date:  2015-07-13       Impact factor: 44.544

7.  Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk.

Authors:  Frederika A van Nimwegen; Michael Schaapveld; Cécile P M Janus; Augustinus D G Krol; Eefke J Petersen; John M M Raemaekers; Wouter E M Kok; Berthe M P Aleman; Flora E van Leeuwen
Journal:  JAMA Intern Med       Date:  2015-06       Impact factor: 21.873

8.  Use of health care services by survivors of childhood and adolescent cancer in Canada.

Authors:  Amanda K Shaw; Lisa Pogany; Kathy N Speechley; Elizabeth Maunsell; Maru Barrera; Leslie S Mery
Journal:  Cancer       Date:  2006-04-15       Impact factor: 6.860

9.  Medical care in long-term survivors of childhood cancer: a report from the childhood cancer survivor study.

Authors:  Paul C Nathan; Mark L Greenberg; Kirsten K Ness; Melissa M Hudson; Ann C Mertens; Martin C Mahoney; James G Gurney; Sarah S Donaldson; Wendy M Leisenring; Leslie L Robison; Kevin C Oeffinger
Journal:  J Clin Oncol       Date:  2008-09-20       Impact factor: 50.717

10.  Subsequent hospitalisation experience of 5-year survivors of childhood, adolescent, and young adult cancer in Scotland: a population based, retrospective cohort study.

Authors:  D H Brewster; D Clark; L Hopkins; J Bauer; S H Wild; A B Edgar; W H Wallace
Journal:  Br J Cancer       Date:  2013-12-24       Impact factor: 7.640

View more
  2 in total

1.  Early Post-Therapy Prescription Drug Usage among Childhood and Adolescent Cancer Survivors.

Authors:  Andrew B Smitherman; Danielle Mohabir; Tania M Wilkins; Julie Blatt; Hazel B Nichols; Stacie B Dusetzina
Journal:  J Pediatr       Date:  2018-02-12       Impact factor: 4.406

2.  Hospitalization and mortality outcomes in the first 5 years after a childhood cancer diagnosis: a population-based study.

Authors:  Angela Steineck; Eric J Chow; David R Doody; Beth A Mueller
Journal:  Cancer Causes Control       Date:  2021-04-09       Impact factor: 2.532

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.